EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-Cancer Prodrug Cyclophosphamide Exerts Thrombogenic Effects on Human Venous Endothelial Cells Independent of CYP450 Activation—Relevance to Thrombosis

Anne Krüger-Genge, Susanne Köhler, Markus Laube iD, Vanessa Haileka, Sandy Lemm iD, Karolina Majchrzak, Sarah Kammerer iD, Christian Schulz, Joachim Storsberg, Jens Pietzsch iD, Jan-Heiner Küpper, Friedrich Jung

Cells · 2023

DOI: 10.3390/cells12151965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Anne Krüger-Genge und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Healthcare, Biomaterials and Cosmeceuticals, Fraunhofer Institute for Applied Polymer Research (IAP), 14476 Potsdam, Germany. Hauptthemen laut MEDLINE: Prodrugs, Neoplasms, Thrombosis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helmholtz-Association, Ministry for Science, Research and Cultural Affairs of Brandenburg, European Fonds of Regional Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer patients are at a very high risk of serious thrombotic events, often fatal. The causes discussed include the detachment of thrombogenic particles from tumor cells or the adverse effects of chemotherapeutic agents. Cytostatic agents can either act directly on their targets or, in the case of a prodrug approach, require metabolization for their action. Cyclophosphamide (CPA) is a widely used cytostatic drug that requires prodrug activation by cytochrome P450 enzymes (CYP) in the liver. We hypothesize that CPA could induce thrombosis in one of the following ways: (1) damage to endothelial cells (EC) after intra-endothelial metabolization; or (2) direct damage to EC without prior metabolization. In order to investigate this hypothesis, endothelial cells (HUVEC) were treated with CPA in clinically relevant concentrations for up to 8 days. HUVECs were chosen as a model representing the first place of action after intravenous CPA administration. No expression of CYP2B6, CYP3A4, CYP2C9 and CYP2C19 was found in HUVEC, but a weak expression of CYP2C18 was observed. CPA treatment of HUVEC induced DNA damage and a reduced formation of an EC monolayer and caused an increased release of prostacyclin (PGI2) and thromboxane (TXA) associated with a shift of the PGI2/TXA balance to a prothrombotic state. In an in vivo scenario, such processes would promote the risk of thrombus formation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsNeoplasmsThrombosisHumansAntineoplastic Agents, AlkylatingEndothelial CellsCyclophosphamideCytochrome P-450 Enzyme System

Stichwörter der Autor:innen

HUVECcancercyclophosphamidecytochrome P450 enzymes (CYP)human umbilical vein endothelial cellsliverthrombosis

Substanzen

ProdrugsAntineoplastic Agents, AlkylatingCyclophosphamideCytochrome P-450 Enzyme System

Autor:innen und Institutionen

  • Department of Healthcare, Biomaterials and Cosmeceuticals, Fraunhofer Institute for Applied Polymer Research (IAP), 14476 Potsdam, Germany.
  • Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology Cottbus-Senftenberg, 01968 Senftenberg, Germany.
  • Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 01328 Dresden, Germany.
  • Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, 01069 Dresden, Germany.
  • Brandenburg University of Technology Cottbus-Senftenberg, Fraunhofer Project Group PZ-Syn of the Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses (IZI-BB), 14476 Potsdam, German…
  • Faculty of Medicine, Private University in the Principality of Liechtenstein (UFL), 9495 Triesen, Liechtenstein.

ORCID-Profile: Markus Laube, Sandy Lemm, Sarah Kammerer, Jens Pietzsch

Förderung

  • Helmholtz-Association
  • Ministry for Science, Research and Cultural Affairs of Brandenburg
  • European Fonds of Regional Development
  • Ministerium für Wirtschaft, Forschung und Kultur
  • Federal Ministry of Education and Research

Zitieren

APA

Krüger-Genge, A., Köhler, S., Laube, M., Haileka, V., Lemm, S., Majchrzak, K., Kammerer, S., Schulz, C., Storsberg, J., Pietzsch, J., Küpper, J. H., & Jung, F. (2023). Anti-Cancer Prodrug Cyclophosphamide Exerts Thrombogenic Effects on Human Venous Endothelial Cells Independent of CYP450 Activation—Relevance to Thrombosis. Cells. https://doi.org/10.3390/cells12151965

Vancouver

Krüger-Genge A, Köhler S, Laube M, Haileka V, Lemm S, Majchrzak K, et al. Anti-Cancer Prodrug Cyclophosphamide Exerts Thrombogenic Effects on Human Venous Endothelial Cells Independent of CYP450 Activation—Relevance to Thrombosis. Cells. 2023. doi:10.3390/cells12151965

BibTeX
@article{KrgerGenge2023,
  author = {Krüger-Genge, Anne and Köhler, Susanne and Laube, Markus and Haileka, Vanessa and Lemm, Sandy and Majchrzak, Karolina and Kammerer, Sarah and Schulz, Christian and Storsberg, Joachim and Pietzsch, Jens and Küpper, Jan-Heiner and Jung, Friedrich},
  title = {Anti-Cancer Prodrug Cyclophosphamide Exerts Thrombogenic Effects on Human Venous Endothelial Cells Independent of CYP450 Activation—Relevance to Thrombosis},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12151965}
}
Kostenlos starten →